Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

Also called NCT07115953

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07115953
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Belgium, Germany, Greece, Ireland, Malaysia, Netherlands, Taiwan, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07115953. Allocation not applicable; no masking; primary purpose treatment. Start 2025-09-22 (actual); primary completion 2027-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
Acronym
SWYFT
Condition
Hypertension
Condition
Vascular Diseases
Condition
Cardiovascular Diseases
Condition
Chronic Kidney Diseases
Condition
Diabetes Mellitus
Intervention (Device)
Symplicity Spyral™ multi-electrode renal denervation system
Lead sponsor
Medtronic Vascular (class: industry)

Record details

Record id
cardio:ct-nct07115953
Content hash
6f015a1e5e03b051b06050d4933c71732ab7ecf40587e7df9e67b93886157529